In summary, our study provides novel insights into the mechanisms underlying resistance to proteasome inhibitors in multiple myeloma and identifies LSD1 as a potential therapeutic target to enhance cell death in both resistant and non-resistant MM cells. The gene discussed is KDM1A; the disease is plasma cell myeloma.